Celldex reports Q1 2023 net loss $29.4M; advances barzolvolimab Phase 2 studies

Celldex Therapeutics, Inc.

2023-Q1 EPS reported -$0.62 revenue$967,000

Q1 2023 net loss $29.4M ($0.62/share); revenue $1.0M (vs $0.2M prior year).
Cash, equivalents & securities $278.4M at March 31, 2023; sufficient through 2025.
Phase 2 CSU enrollment completion expected Q3 2023; topline data late 2023/Q1 2024.
Phase 2 EoE study initiation expected June 2023; CDX-585 enters clinic mid-2023.
R&D expenses $26.8M (up from $17.1M) driven by barzolvolimab trials and manufacturing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Celldex Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2023

View on SEC.gov

Browse all earnings releases →

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-002887

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.